Skip to content
Bamboo WorksBamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Everest Medicines

Everest makes mRNA vaccines

Everest Medicines drives growth with AI-powered mRNA pipeline

The company said the U.S. FDA has cleared the IND application for its self-developed EVM14, a tumor-associated antigen vaccine Key Takeaways: The FDA has cleared Everest Medicine’s EVM14 cancer vaccine…
March 25, 2025
1952.HK

BRIEF: Everest unveils positive results for kidney drug EVER001 in Phase 1b/2a trial

Everest Medicines (1952.HK) announced on Wednesday that its EVER001, a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor for treatment of primary membranous nephropathy (pMN), showed positive results in its…
December 5, 2024
1952.HK
Illustration of McDonald's Big Mac

A McDonald’s Valuation Downsize, and New Medical Plan Additions

The value of McDonald's China operation has plunged by more than half in the last year.  And 91 companies got their drugs added to China's national health plan By Doug…
December 3, 2024
Everest's nefecon included on national drug list

Everest gets boost from core product Nefecon’s inclusion in China’s national health plan

Nefecon’s addition to China’s NRDL will increase its reach and market share, lifting the drug’s competitive advantage and brand recognition Key Takeaways: Everest Medicines’ Nefecon kidney drug was approved for…
December 2, 2024
1952.HK
Everest Medicines eyes cash break even

Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound

The innovative drug maker’s stock jumped more than 18% in a single day on high hopes for inclusion of its blockbuster new drug, Nefecon, in China’s national reimbursement drug list…
October 24, 2024
1952.HK
Established in 2017, Everest develops cancer and autoimmune disorder drugs and listed in Hong Kong in 2020.

FAST NEWS: Everest Medicines loss widens on drug commercialization

The Latest: Everest Medicines Ltd. (1952.HK) announced Tuesday its revenue for the first half of this year surged about 33 times to 302 million yuan ($42.3 million), while its net loss jumped 49%…
August 28, 2024
1952.HK
The biotech, which obtained rights to novel drugs for use in the Chinese market, has announced a plan to wind up its business and delist from the Nasdaq just four years after being founded.

With no cure in sight, drugs firm LianBio begins exit strategy

The biotech, which obtained rights to novel drugs for use in the Chinese market, has announced a plan to wind up its business and delist from the Nasdaq just four…
February 23, 2024
LIAN.US
Load more

Recent Articles

Everest makes mRNA vaccines
March 25, 2025

Everest Medicines drives growth with AI-powered mRNA pipeline

1952.HK
December 5, 2024

BRIEF: Everest unveils positive results for kidney drug EVER001 in Phase 1b/2a trial

1952.HK
December 3, 2024

A McDonald’s Valuation Downsize, and New Medical Plan Additions

December 2, 2024

Everest gets boost from core product Nefecon’s inclusion in China’s national health plan

1952.HK
October 24, 2024

Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound

1952.HK
August 28, 2024

FAST NEWS: Everest Medicines loss widens on drug commercialization

1952.HK
February 23, 2024

With no cure in sight, drugs firm LianBio begins exit strategy

LIAN.US

RECENT ARTICLES

  1. Everest makes mRNA vaccines
    March 25, 2025
    Everest Medicines drives growth with AI-powered mRNA pipeline
    1952.HK
  2. December 2, 2024
    Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
  3. March 20, 2025
    A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
  4. January 9, 2025
    Cancer drug maker Genfleet joins Hong Kong IPO influx
  5. December 5, 2024
    BRIEF: Everest unveils positive results for kidney drug EVER001 in Phase 1b/2a trial
    1952.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.